GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (FRA:TGK) » Definitions » Valuation Rank

Precipio (FRA:TGK) Valuation Rank


View and export this data going back to . Start your Free Trial

What is Precipio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Precipio Valuation Rank Related Terms

Thank you for viewing the detailed overview of Precipio's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Precipio (FRA:TGK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (FRA:TGK) » Definitions » Valuation Rank
Comparable Companies
LMDXF XWEL IDXG CNTG MYNZ RNVA PCHM CHEK DMTK NDRA TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN
Traded in Other Exchanges
PRPO:USA
Address
4 Science Park, New Haven, CT, USA, 06511
Website
https://www.precipiodx.com
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.